Biblio

13 resultats trouvés
Filtres: Auteur is Lepiller, Q.  [Clear All Filters]
D
Razanamahery J., Soumagne T., Humbert S., Brunel A.S, Lepiller Q., Daguindau E., Mansi L., Chirouze C., Bouiller K..  2020.  Does type of immunosupression influence the course of Covid-19 infection? JOURNAL OF INFECTION. 81:E132-E135.
E
Schuffenecker I., Mirand A., Josset L., Henquell C., Hecquet D., Pilorge L., Petitjean-Lecherbonnier J., Manoha C., Legoff J., Deback C. et al..  2016.  Epidemiological and clinical characteristics of patients infected with enterovirus D68, France, July to December 2014. EUROSURVEILLANCE. 21:30226.
F
Klopfenstein T., Kadiane-Oussou N.J, Toko L., Royer P-Y, Lepiller Q., Gendrin V, Zayet S..  2020.  Features of anosmia in COVID-19. MEDECINE ET MALADIES INFECTIEUSES. 50:436-439.
H
Winiszewski H., Daguindau E., Chaignat C., Piton G., Bouiller K., Lepiller Q., Klopfenstein T..  2020.  HHV8 inflammatory cytokine syndrome mimicking septic shock. MEDECINE ET MALADIES INFECTIEUSES. 50:300-302.
L
Alain S., Feghoul L., Girault S., Lepiller Q., Frobert E., Michonneau D., Berceanu A., Ducastelle-Lepretre S., Tilloy V, Guerin E. et al..  2020.  Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practice. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 75:2253-2257.
M
Lions C., Cabras O., Cotte L., Huleux T., Gagneux-Brugnon A., Makinson A., Cabie A., Bonnet B., Duvivier C., Hocqueloux L. et al..  2019.  Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort. BMC INFECTIOUS DISEASES. 19:278.
Bellanger A.-P, Navellou J.-C, Lepiller Q., Brion A., Brunel A.-S, Millon L., Berceanu A..  2021.  Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. INFECTIOUS DISEASES NOW. 51:633-635.
N
Wirden M, De Oliveira F, Bouvier-Alias M, Lambert-Niclot S, Chaix M-L, Raymond S, SI-Mohammed A, Alloui C, Andre-Garnier E, Bellecave P et al..  2019.  New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. EUROSURVEILLANCE. 24:1800658.
Morgat M., Bouiller K., Vuillemenot J.B, Puget L., Marty-Quinternet S., Leblanc T., Jeannot K., Chirouze C., Hustache-Mathieu L., Lepiller Q..  2021.  Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital. INFECTIOUS DISEASES NOW. 51:357-361.
P
Razanamahery J., Malinowski L., Humbert S., Brunel A.S, Lepiller Q., Chirouze C., Bouiller K..  2020.  Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response. MEDECINE ET MALADIES INFECTIEUSES. 50:625-627.
Razanamahery J., Malinowski L., Humbert S., Brunel A.S, Lepiller Q., Chirouze C., Bouiller K..  2020.  Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response. MEDECINE ET MALADIES INFECTIEUSES. 50:625-627.
R
Debernardi A., Jarassier W., Soret C., Mougin C., Alizon S., Bravo I.G, Guenat D., Pretet J.L, Lepiller Q..  2021.  Repurposing the Hybrid Capture 2 (HC2) screening test for whole-genome sequencing of human papillomaviruses. ARCHIVES OF VIROLOGY. 166:3421-3425.
S
Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M et al..  2019.  Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 74:1417-1424.